Experimental: PreOp, NutriciaNordica AB
Dietary SupplementOther names: PreOp, serial number 27 62 95, NutriciaNordica AB
NCT Number: NCT01774084
The purpose of this study is to determine whether preload of carbohydrate or water before elective hip replacement improve insulin sensitivity and or beta cell function in human.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 4
Södersjukhuset AB, Stockholm, Sweden
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: PreOp, serial number 27 62 95, NutriciaNordica AB
Time frame: Morning before surgery and up to two days after surgery
Insulin sensitivity is measured by euglycemic hyperinsulinemic clamp
Time frame: Morning before surgery and up to two days after surgery
Beta cell function is measured with intravenous glucose tolerance test (IVGTT)
Karolinska Institutet
Other
Insulin Sensitivity and Beta Cell Function After Carbohydrate Loading in Hip Replacement Surgery: A Randomised Doubled-blinded Control Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04264897
Aging, Chronic Disease
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT05764200
Glucose Metabolism Disorders, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Maastricht, Netherlands
View Trial DetailsNCT07194772
Glucose Homeostasis, Glucose Intolerance
Ottawa, Ontario, Canada
View Trial DetailsNCT03479671
Diabetes Mellitus, Diabetes Mellitus, Type 2
Philadelphia, Pennsylvania, United States
View Trial Details